These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 12406006)

  • 1. Relationship between the clinical manifestations of sickle cell disease and the expression of adhesion molecules on white blood cells.
    Okpala I; Daniel Y; Haynes R; Odoemene D; Goldman J
    Eur J Haematol; 2002 Sep; 69(3):135-44. PubMed ID: 12406006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. l-selectin gene polymorphisms and complications of sickle cell disease.
    Ugochukwu CC; Okpala I; Pantelidis P; Inusa B; Ibegbulam O; Onyekwere O
    Int J Lab Hematol; 2008 Aug; 30(4):312-6. PubMed ID: 18665829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Markers of endothelial dysfunction and leucocyte activation in Saudi and non-Saudi haplotypes of sickle cell disease.
    Al Najjar S; Adam S; Ahmed N; Qari M
    Ann Hematol; 2017 Jan; 96(1):141-146. PubMed ID: 27686084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood mononuclear cells and platelets have abnormal fatty acid composition in homozygous sickle cell disease.
    Ren H; Okpala I; Ghebremeskel K; Ugochukwu CC; Ibegbulam O; Crawford M
    Ann Hematol; 2005 Sep; 84(9):578-83. PubMed ID: 15809883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leukocyte adhesion and the pathophysiology of sickle cell disease.
    Okpala I
    Curr Opin Hematol; 2006 Jan; 13(1):40-4. PubMed ID: 16319686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erythroid adhesion molecules in sickle cell disease: effect of hydroxyurea.
    Cartron JP; Elion J
    Transfus Clin Biol; 2008; 15(1-2):39-50. PubMed ID: 18515167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The fucosylation inhibitor, 2-fluorofucose, inhibits vaso-occlusion, leukocyte-endothelium interactions and NF-ĸB activation in transgenic sickle mice.
    Belcher JD; Chen C; Nguyen J; Abdulla F; Nguyen P; Nguyen M; Okeley NM; Benjamin DR; Senter PD; Vercellotti GM
    PLoS One; 2015; 10(2):e0117772. PubMed ID: 25706118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hydroxyurea corrects the dysregulated L-selectin expression and increased H(2)O(2) production of polymorphonuclear neutrophils from patients with sickle cell anemia.
    Benkerrou M; Delarche C; Brahimi L; Fay M; Vilmer E; Elion J; Gougerot-Pocidalo MA; Elbim C
    Blood; 2002 Apr; 99(7):2297-303. PubMed ID: 11895759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The intriguing contribution of white blood cells to sickle cell disease - a red cell disorder.
    Okpala I
    Blood Rev; 2004 Mar; 18(1):65-73. PubMed ID: 14684149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endothelial function in patients with sickle cell anemia during and after sickle cell crises.
    Blum A; Yeganeh S; Peleg A; Vigder F; Kryuger K; Khatib A; Khazim K; Dauerman H
    J Thromb Thrombolysis; 2005 Apr; 19(2):83-6. PubMed ID: 16052296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Neutrophil Adhesive Events to Address Vaso-Occlusive Crisis in Sickle Cell Patients.
    Morikis VA; Hernandez AA; Magnani JL; Sperandio M; Simon SI
    Front Immunol; 2021; 12():663886. PubMed ID: 33995392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma levels of TNF-alpha in sickle cell patients receiving hydroxyurea.
    Tavakkoli F; Nahavandi M; Wyche MQ; Perlin E
    Hematology; 2004 Feb; 9(1):61-4. PubMed ID: 14965870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokines and soluble adhesion molecules in sickle cell anemia patients during hydroxyurea therapy.
    Saleh AW; Duits AJ; Gerbers A; de Vries C; Hillen HF
    Acta Haematol; 1998; 100(1):26-31. PubMed ID: 9691143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flow adhesion of whole blood to P-selectin: a prognostic biomarker for vaso-occlusive crisis in sickle cell disease.
    Hines PC; Callaghan MU; Zaidi AU; Gao X; Liu K; White J; Tarasev M
    Br J Haematol; 2021 Sep; 194(6):1074-1082. PubMed ID: 34472086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammatory potential of neutrophils detected in sickle cell disease.
    Lum AF; Wun T; Staunton D; Simon SI
    Am J Hematol; 2004 Jun; 76(2):126-33. PubMed ID: 15164377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levels of endothelial, neutrophil and platelet-specific factors in sickle cell anemia patients during hydroxyurea therapy.
    Saleh AW; Hillen HF; Duits AJ
    Acta Haematol; 1999; 102(1):31-7. PubMed ID: 10473885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adhesion molecules and high-sensitivity C-reactive protein levels in patients with sickle cell beta-thalassaemia.
    Kanavaki I; Makrythanasis P; Lazaropoulou C; Kattamis A; Tzanetea R; Kalotychou V; Rombos I; Papassotiriou I
    Eur J Clin Invest; 2012 Jan; 42(1):27-33. PubMed ID: 21615396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levels of Soluble Endothelium Adhesion Molecules and Complications among Sickle Cell Disease Patients in Ghana.
    Antwi-Boasiako C; Donkor ES; Sey F; Dzudzor B; Dankwah GB; Otu KH; Doku A; Dale CA; Ekem I
    Diseases; 2018 Apr; 6(2):. PubMed ID: 29690499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adherent leukocytes capture sickle erythrocytes in an in vitro flow model of vaso-occlusion.
    Finnegan EM; Turhan A; Golan DE; Barabino GA
    Am J Hematol; 2007 Apr; 82(4):266-75. PubMed ID: 17094094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
    Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.